Related by context. All words. (Click for frequent words.) 72 PI3K/Akt pathway inhibitor 69 trastuzumab DM1 T DM1 69 Phase Ib study 68 histone deacetylase HDAC inhibitor 68 ongoing Phase 1b 66 EOquin TM 66 Aplidin R 66 PDX pralatrexate 66 YONDELIS 66 mertansine 66 Phase Ib II 66 crizotinib PF # 66 initiated Phase Ib 65 fosbretabulin 65 anticancer compound 65 apoptosis inducer 65 Amrubicin 65 PSMA ADC 65 novel histone deacetylase 65 depsipeptide 65 radiation sensitizer 64 Panzem R 64 Tarceva TM 64 Alocrest 64 liposomal formulation 64 Cloretazine ® 64 relapsed refractory multiple myeloma 64 randomized controlled Phase 64 Phase 1b clinical trials 64 preclinical efficacy 64 Tesetaxel 64 Junovan TM 64 FOLOTYN ® 64 solithromycin 64 gallium containing 64 Phase IIb clinical trials 64 Phase 1a clinical 63 MAGE A3 ASCI 63 huN# DM1 63 phase IIb trial 63 alvespimycin 63 Quinamed 63 potent antiproliferative 63 multicenter Phase 63 huC# DM4 63 Ceflatonin R 63 mitogen activated ERK kinase 63 dose escalation clinical 63 ELACYT 63 SUCCEED trial 63 pharmacokinetic PK study 63 VNP#M 63 Triapine R 63 lexidronam injection 63 Phase IIIb clinical 63 telomerase inhibitor drug 63 MEK inhibitor 63 JAK1 63 Phase 2a trial 63 PROSTASCINT R 63 Cloretazine 63 Phase #b/#a clinical 63 Solazed TM 63 Omacetaxine 63 MGd 63 placebo controlled Phase 63 HCV RESPOND 2 63 phase IIa clinical 63 Safinamide 63 OvaRex ® MAb 63 seliciclib CYC# 63 phase IIb clinical 63 ASCO abstract 63 Xanafide 63 INCB# [001] 63 BiTE R 63 forodesine 63 pan HDAC inhibitor 63 generation purine nucleoside 62 hyaluronidase enzyme 62 PEG SN# 62 BrachySil TM 62 brivanib 62 BR.# 62 non nucleoside inhibitor 62 Initiated Phase 62 darinaparsin ZIO 62 PrevOnco ™ 62 lorvotuzumab mertansine 62 bortezomib Velcade ® 62 Pivotal Phase III 62 adecatumumab MT# 62 neratinib 62 phase III isavuconazole 62 ganetespib 62 Hedgehog Pathway Inhibitor 62 LymphoStat B TM 62 Phase III randomized controlled 62 phase Ib 62 Yondelis ® 62 multicenter Phase III 62 PDE4 inhibitor 62 Onconase 62 thalidomide Thalomid 62 Litx 62 Panzem R NCD 62 rALLy clinical trial 62 SinuNase ™ 62 trastuzumab emtansine T DM1 62 EZN 62 Phase 2a clinical 62 sunitinib Sutent ® 62 verteporfin 62 IL# PE#QQR 62 Cloretazine R 62 Panzem NCD 62 PNP inhibitor 62 Kahalalide F 62 oral prodrug 62 Phase 2b monotherapy 62 AQ4N 62 Azedra 62 Hsp# Inhibitor 62 Phase III Clinical Trials 62 YONDELIS R 61 candidate CRLX# 61 assessing T DM1 61 UPLYSO 61 sulodexide 61 HuMax CD4 61 rALLy trial 61 CRMD# 61 orally administered inhibitor 61 class anticancer quinolone 61 HER2 positive metastatic breast 61 Neulasta R 61 EGFR HER2 61 Phase III ALLEGRO 61 Virulizin R 61 multicenter Phase II 61 Archexin 61 dosing cohort 61 PRTX 61 vidofludimus 61 including eniluracil ADH 61 Voreloxin 61 Altropane 61 Perifosine 61 Phase 2b clinical 61 ocular formulation 61 Genta Incorporated OTCBB GETA 61 ARRY # 61 radiotherapeutic 61 Azedra ™ 61 microtubule inhibitor 61 sodium thiosulfate STS 61 oral ridaforolimus 61 Solazed 61 HGS# 61 OXi# 61 P#X# antagonist 61 ZYBRESTAT TM 61 dose escalation Phase 61 BRIM2 61 Cotara ® 61 EndoTAG 61 Androxal TM 61 Matrix Phase 2b 61 small molecule Hedgehog 61 romidepsin novel 61 Aflibercept 61 phase 2a 61 MOZOBIL 61 GW# [003] 61 Vicinium TM 61 metastatic CRC 61 perifosine 61 ZEVALIN ® 61 please visit www.advaxis.com 61 NXL# 61 IMiDs R 61 refractory chronic lymphocytic 61 phase Ib clinical 61 AEG# 61 LUX Lung 61 telaprevir dosing 61 Phase Ib clinical 61 BIBW 61 nitric oxide donating prostaglandin 61 receptor inhibitor 61 brivaracetam 61 TKB# 61 CCX# 61 randomized discontinuation trial 61 pharmacokinetic PK 61 Exherin 61 ORENCIA R 61 Hedgehog pathway inhibitor 61 evaluating tivozanib 61 Aplidin 61 EndoTAG TM -1 61 GAMMAGARD 61 OncoGel 61 PLK1 SNALP 61 HCD# [002] 61 Phase 1b dose escalation 61 recurrent glioblastoma multiforme 61 somatostatin analogue 61 initiated Phase 1b 61 HCV protease inhibitor 60 indibulin 60 Carfilzomib 60 Cloretazine R VNP#M 60 Pathway Inhibitor 60 proteasome inhibitor 60 PANVAC VF 60 Shigamabs ® 60 axitinib 60 ospemifene 60 Marqibo TM 60 novel synthetic peptide 60 Phase Ib 60 phase IIb study 60 Pyridorin 60 novel VDA molecule 60 Zenvia ™ 60 HCV SPRINT 60 histamine dihydrochloride 60 IAP inhibitor 60 IMiDs ® 60 CYC# 60 Targretin capsules 60 IMGN# 60 HuMax EGFr 60 Exherin TM 60 refractory multiple myeloma 60 Nexavar sorafenib 60 Phase 2b trial 60 receptor tyrosine kinase inhibitor 60 Kepivance 60 imatinib Gleevec ® 60 Diabetic Macular Edema DME 60 Plicera 60 Velcade bortezomib 60 pharmacodynamic PD 60 randomized Phase 2b 60 highly selective inhibitor 60 RhuDex ® 60 PrevOnco 60 Phase #b/#a trial 60 ENMD # 60 AP# [003] 60 immune modulatory 60 prospective multicenter study 60 Actemra tocilizumab 60 generation Hsp# inhibitor 60 Initiate Phase 60 PRNewswire FirstCall Genta Incorporated 60 ALGRX 60 BiTE antibody 60 ILUVIEN ® 60 Zybrestat 60 gemcitabine Gemzar ® 60 Traficet EN 60 vascular disrupting agent 60 BRIM3 60 integrin inhibitor 60 teriflunomide 60 PXD# 60 NASDAQ CYTK announced 60 targeted radiotherapeutic 60 Zenvia Phase III 60 Elagolix 60 2 methoxyestradiol 60 NASDAQ CXSP announced 60 BAY #-# 60 investigational oral hepatitis C 60 alemtuzumab Campath 60 nucleotide analog 60 Cleviprex TM clevidipine 60 Squalamine 60 MNTX 60 relapsed MM 60 JZP 60 samarium Sm 60 ruxolitinib 60 Pyridorin TM 60 Nanobody 60 GetGoal Phase III 60 tiapamil 60 Survivin antagonist 60 CTAP# Capsules 60 clevidipine 60 GSK# [001] 60 TPI ASM8 60 PRECISE trial 60 RenalGuard System TM 60 MGCD# [001] 60 phase IIb III 60 SinuNase TM 60 Trofex 60 XYOTAX TM 60 Phase 1b trial 60 Announces Poster Presentations 60 histone deacetylase inhibitor 60 Enzastaurin 60 Xeloda ® 60 Blinatumomab 60 vivo preclinical 60 phase IIa 60 Randomized Phase 60 rxRNA 60 GMX# 60 prokinetic agent 60 biliary tract cancer 60 ATL/TV# 60 SAR# [004] 59 Azedra TM 59 vapreotide acetate 59 ThermoDox R 59 GEM OS1 59 acyclovir Lauriad R 59 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 59 desvenlafaxine succinate 59 trial evaluating PRX# 59 registrational trial 59 small molecule activator 59 tumor xenograft models 59 demonstrated antitumor activity 59 recurrent malignant glioma 59 potently inhibits 59 Ambrisentan 59 non nucleoside HCV 59 Raptiva R 59 pralatrexate 59 Phase IIB 59 CLARITY study 59 ADVANCE PD 59 NASDAQ PCYC 59 EFAPROXYN 59 highly selective adenosine 59 Nasdaq PGNX today 59 tubulin inhibitor 59 Genasense ® 59 Pharmacodynamic 59 bortezomib Velcade 59 Vitaxin 59 telomerase therapeutic 59 novel prodrug 59 evaluating bafetinib 59 Combidex 59 TREANDA 59 liver resection surgeries 59 irreversible inhibitor 59 ularitide 59 amrubicin 59 Phase IIa trial 59 R#/MEM # 59 AKT inhibitor 59 GVAX ® 59 lymphoid malignancies 59 OvaRex R 59 AEGR 59 leading oral taxane 59 Factor VIIa 59 ceftazidime 59 MIVI III 59 docetaxel Taxotere ® 59 CR# vcMMAE 59 Soliris eculizumab 59 Teysuno 59 AZX# 59 QUADRAMET R 59 LEUKINE 59 treatment naive genotype 59 Sym# 59 RAV# 59 kidney urologic 59 pomalidomide 59 ZACTIMA 59 Sudhir Agrawal D.Phil 59 TG MV 59 Loramyc R 59 Xcellerated T Cells 59 ATL# [002] 59 Phase #/#a trial 59 TÎ ² 4 59 Troxatyl 59 deforolimus 59 #th Annual Interscience 59 gefitinib Iressa 59 SPRYCEL ® 59 prucalopride 59 Alferon N 59 TRISENOX 59 XL# [003] 59 GRN# 59 ara C 59 enzastaurin 59 Metastatic Melanoma 59 hypoxia selective 59 eniluracil 59 polycythemia vera PV 59 HIV integrase inhibitor 59 Epratuzumab 59 fidaxomicin Phase 59 HepaSphere 59 Genasense ® oblimersen 59 SNT MC# 59 RH1 59 Combination REOLYSIN R 59 BXT # 59 tesetaxel 59 tumors GIST 59 elotuzumab 59 sorafenib Nexavar 59 dose cohort 59 REMINYL ® 59 EXPAREL ™ 59 gastrointestinal disorders ATI 59 AZILECT R 59 Commence Phase 59 IMiD 59 ixabepilone 59 inhaled AAT 59 radiation dosimetry 59 inhibitor RG# 59 trastuzumab DM1 59 NOX E# 59 Inc. Amex SYI 59 CINTREDEKIN BESUDOTOX 59 ICA # 59 Qutenza TM 59 LUNESTA TM 59 Curaxin CBLC# 59 VEGFR2 inhibitor 59 BLA submission 59 pertuzumab 59 docetaxel Taxotere R 59 Augment Injectable 59 Chronic Lymphocytic Leukemia CLL 59 targeted antifolate 59 PKC# 59 CLORETAZINE TM VNP#M 59 selective modulator 59 Aganocide R 59 Ceflatonin ® 59 vernakalant hydrochloride 59 EOquin 59 INCB# [002] 59 Silodosin 59 Phase IIa trials 59 UVIDEM 59 Tezampanel 59 IIb clinical trial 59 Glufosfamide 59 Allovectin 7 ® 59 vinca alkaloid 59 talactoferrin 59 diabetic neuropathic pain 59 Bayer HealthCare Onyx Pharmaceuticals 59 orally bioavailable 59 XL# XL# 59 intravesical infusion therapy 59 OncoVEX 59 CDK inhibitor 59 Phenoptin 59 Afinitor everolimus 59 IPL# 59 maturation inhibitor 59 Phase 2b Clinical Trial 59 Ozarelix 59 Tanespimycin 59 Zolinza 59 APOPTONE 59 refractory cutaneous T 59 erlotinib Tarceva ® 59 gemcitabine cisplatin 59 adecatumumab 59 dosing cohorts 59 capecitabine Xeloda R 59 mRCC 59 Immunotherapeutic 59 Phase 1b clinical 59 acyclovir Lauriad ® 58 Proellex TM 58 ON #.Na 58 Alzhemed TM 58 EGS# 58 XOMA 3AB 58 AACR #st Annual Meeting 58 GLP toxicology studies 58 investigational humanized monoclonal antibody 58 Hodgkin lymphoma HL 58 novel defensin mimetic 58 ENESTnd 58 entitled Synergistic 58 Bezielle 58 CRLX# 58 Virulizin ® 58 relapsed multiple myeloma 58 GEM OS2 58 ExTRACT TIMI 58 IV Busulfex 58 investigational pan BCR 58 DermTech International 58 Atiprimod 58 Genasense R oblimersen 58 TAFA# 58 inhaled iloprost 58 Neulasta ® 58 Proxinium TM 58 dose escalation trial 58 Apoptone 58 aurora kinase 58 RGB # 58 mapatumumab 58 hoFH 58 Gastrointestinal Cancers Symposium 58 paclitaxel Taxol ® 58 BAL# [002] 58 NVA# 58 Cyclooxygenase Inhibiting Nitric Oxide 58 HGS ETR2 58 immunosuppressive compound 58 Dalbavancin 58 Hepatocellular Carcinoma HCC 58 ofatumumab HuMax CD# 58 JAK2 inhibitor 58 SABCS 58 PROSTVAC ® 58 retapamulin 58 PRE SURGE 58 NASDAQ OMER 58 evaluating satraplatin 58 IMiDs ® compound 58 ancrod 58 Nasdaq PARD 58 Alfacell proprietary ribonuclease 58 PF # [001] 58 herpetic keratitis 58 XL# anticancer compounds 58 AACR NCI EORTC 58 MERLIN TIMI 58 antibody MAb 58 humanized anti 58 NEBIDO R 58 Allovectin 7 58 initiate Phase 1b 58 APEX PD 58 HQK 58 Novel Oral 58 ENDEAVOR IV 58 Etoposide 58 Initiates Clinical 58 Talabostat 58 investigational immunotherapy 58 NSABP B 58 drug GAP #B# 58 vascular disrupting 58 ThermoDox ® clinical 58 Advanced Renal Cell 58 CYT# potent vascular disrupting 58 Triolex 58 anti leukemic 58 Tarvacin TM 58 Phase IIIb 58 oral antiviral 58 registrational 58 essential thrombocythemia ET 58 humanized monoclonal 58 monoclonal antibody conjugated 58 Anturol TM 58 selective kinase inhibitor 58 Files Investigational 58 Phase IIb III 58 RezularTM 58 Phase #b/#a 58 Protease Inhibitor 58 Trodusquemine 58 IIa trials 58 BCX# 58 IPLEX 58 Fodosine 58 plasma kallikrein inhibitor 58 LB# [003] 58 evaluating mipomersen 58 BiTE antibody MT# 58 selective adenosine 58 TYKERB 58 preclinical pharmacokinetic 58 virus HCV protease inhibitor 58 Zemiva ™ 58 Darinaparsin 58 Trofex TM 58 cariprazine 58 hypoxia activated prodrug 58 MYDICAR ® 58 TELINTRA 58 xenograft models 58 Completes Patient Enrollment 58 tanespimycin 58 evaluating REVLIMID 58 Selective Electrochemical Tumor Ablation 58 DAS# Fludase ® 58 Anavex #-# 58 PSN# [002] 58 Phase Ib clinical trials 58 CINOD 58 Antiangiogenic 58 Iloperidone 58 Medicinal Chemistry Letters 58 sunitinib malate 58 Degarelix 58 galiximab 58 investigational compounds 58 HDAC Inhibitor 58 Xelox 58 Deforolimus 58 Aurora Kinase 58 immuno modulatory 58 multicenter randomized placebo controlled 58 mGluR5 negative 58 Gemzar ® 58 sorafenib tablets 58 GATTEX ® 58 MAP# 58 ToGA 58 GRN#L 58 Levoleucovorin 58 Tasimelteon 58 RSD# oral 58 SCCHN 58 investigational protease inhibitor 58 dasatinib Sprycel ® 58 RELOVAIR ™ 58 Natalizumab 58 XmAb# 58 Alvesco R 58 ENMD 58 Kamada AAT 58 Brentuximab Vedotin SGN 58 Hematological Malignancies 58 IIa trial 58 NN# [001] 58 vorinostat 58 reslizumab 58 KSP inhibitor 58 phase IIb 58 haematologic 58 Lenocta 58 ALN HPN 58 bendamustine 58 REVIVE Diabetes 58 lucinactant 58 REGENERX BIOPHARMACEUTICALS INC. 58 vitro cytotoxicity 58 CB2 selective receptor agonist 58 Pivotal Clinical Trial 58 PEGylated interferon 58 fidaxomicin Phase 3 58 potent anticancer 58 null responder 58 mitomycin 58 NASDAQ INGN 58 investigational compound 58 cathepsin K inhibitor 58 cilengitide 58 INC# 58 novel peptide 58 GRNVAC1 58 OPAXIO 58 Biological Therapy 58 intranasal formulation 58 Initiates Enrollment 58 goserelin 58 FDA Approvable Letter 58 abstracts summarizing 58 IMA# 58 Clevudine 58 multi kinase inhibitor 58 mg administered orally 58 Hsp# inhibitor 58 pemetrexed Alimta 58 Personalized Immunotherapy 58 Nasdaq OMER 58 urocortin 2 58 dextromethorphan quinidine 58 selectively inhibits 58 Aurexis 58 Zemiva TM 58 pain palliation 58 Parathyroid Hormone 58 FavId 58 XL# XL# XL# 58 volociximab 58 DermaVir Patch 58 Debio 58 Modrenal R 58 OMNARIS HFA 58 HoFH 58 pediatric acute lymphoblastic 58 PEG IFN 58 ONX 58 BAL# [001] 58 diarrhea predominant irritable 58 zanolimumab 58 tramiprosate Alzhemed TM 58 TLK# 58 Phase IIa clinical 58 Cimzia ® certolizumab pegol 58 Nasdaq IDRA today 58 Gleevec resistant 58 romiplostim 58 miRview ™ squamous 58 ProLindac TM 58 Frova ® 58 Telatinib 58 silodosin 57 PROSTVAC TM 57 hypoxia inducible factor 57 Telintra 57 Sanvar R 57 PHX# 57 Phase 2b study 57 modified glutathione analog 57 cannabinor 57 antisense inhibitor 57 mTOR inhibitor 57 Annamycin 57 platinum refractory 57 Onco TCS 57 dacarbazine DTIC 57 Solorel TM 57 CD# CEA 57 AzaSite Plus 57 darinaparsin 57 randomized Phase III 57 Topline Results 57 registrational Phase 57 protein kinase inhibitor 57 TYZEKA 57 Vion Pharmaceuticals 57 Pemetrexed 57 drug pipeline TAFA# 57 Phase IIIb study 57 Presents Preclinical 57 Guanilib 57 cutaneous T 57 Vidaza R 57 ALN TTR 57 cell lymphoma CTCL 57 ADP receptor antagonist 57 ofatumumab 57 LE SN# 57 ORENCIA ® 57 novel anticancer 57 protein tyrosine phosphatase 1B 57 PEP# [003] 57 Chemophase 57 lomitapide 57 Clinical Oncology Annual Meeting 57 TACI Ig 57 JAK inhibitor 57 Phase 2a clinical trials 57 Neuradiab 57 intravenous acetaminophen 57 NP2 Enkephalin 57 FAME Study 57 pralatrexate injection 57 Phase Ia 57 teduglutide 57 blinatumomab 57 IMPACT DCM 57 IRX 2 57 Dacogen injection 57 HCV polymerase inhibitors 57 veltuzumab 57 Luteinizing Hormone Releasing Hormone 57 HuMax HepC TM 57 AMEX RGN 57 Phase III Clinical Trial 57 delafloxacin 57 dose cohorts 57 ChemGenex Pharmaceuticals Limited 57 oral COTI 57 CANCIDAS 57 BEMA TM Fentanyl 57 ARIKACE 57 polymerase inhibitor 57 metaglidasen 57 Nasdaq VRTX today 57 sodium glucose cotransporter 57 double blinded placebo 57 HDL Selective Delipidation 57 Gentamicin Surgical Implant 57 Lenocta TM 57 ANTEGREN 57 panitumumab Vectibix 57 product candidate Lpathomab 57 novel orally bioavailable 57 prostone 57 arsenic trioxide injection 57 Increlex R 57 Glypromate 57 selective androgen receptor modulator 57 Nasdaq ACEL 57 ZYBRESTAT fosbretabulin 57 MEND CABG 57 PRLX # 57 palifosfamide Zymafos TM 57 hormone LHRH antagonist 57 Aganocide ® 57 topical formulation 57 ASCO Annual Meeting 57 INTERCEPT platelets 57 Azilect ® 57 Dyloject TM 57 placebo controlled clinical 57 ASH Annual Meeting 57 PEGylated 57 quinolone antibiotic 57 BENLYSTA ® 57 cetuximab Erbitux R 57 RE SURGE 57 MT#/MEDI-# 57 CBLC# 57 BrachySil 57 Hematology Annual Meeting 57 OMP #M# 57 ESBA# 57 LibiGel ® 57 nucleoside analog 57 Fx #A 57 GAP #B# 57 tolevamer 57 Marketing Authorisation Application MAA 57 Gleevec imatinib mesylate 57 Telavancin 57 RECORD1 57 etanercept Enbrel 57 LHRH antagonist 57 thorough QT 57 Pivotal Phase 57 VELCADE melphalan 57 Phase #/#a 57 Pivotal Study 57 torezolid phosphate 57 Phase III Pivotal 57 Cephalon Oncology 57 Seliciclib 57 L Annamycin 57 MKC# MT 57 CD3 monoclonal antibody 57 elacytarabine 57 metastatic renal cell carcinoma 57 miconazole Lauriad ® 57 Tarmogen 57 CytoFabTM 57 sapacitabine 57 CAMPATH 57 NS#/#A protease 57 Cimzia TM 57 Clinical Trial Results 57 anti fibrotic 57 octreotide acetate 57 Late Breaker 57 Allovectin 7 R 57 TASKi2 57 mg/m2 cohort 57 NOD SCID mice 57 CLIRS trial 57 glufosfamide 57 RE LY ® 57 Iluvien ® 57 trabectedin 57 midstage clinical 57 Ceflatonin 57 HIV integrase inhibitors 57 Nasdaq DVAX 57 favorable pharmacokinetic profile 57 LEP ETU 57 generation PNP inhibitor 57 EVIZON TM 57 DDP# 57 Tamibarotene 57 Exelixis compounds 57 methionine aminopeptidase 57 opioid induced bowel dysfunction 57 myeloproliferative disorders 57 Oral NKTR 57 acadesine 57 SAR# [002] 57 alkylating agent 57 cetuximab Erbitux ® 57 Nasdaq ACHN 57 Ecallantide 57 rNAPc2 57 antineoplastic 57 Prostate AdenoCarcinoma Treatment 57 treat chronic sinusitis 57 generation URAT1 inhibitor 57 multikinase inhibitor 57 oral deforolimus 57 KNS # 57 anticancer agent 57 CHAMPION PCI 57 ALK inhibitor 57 Glybera 57 isoform selective 57 CYT# 57 TOLAMBA 57 AMPAKINE CX# 57 NEUVENGE 57 treatment naïve genotype 57 Cintredekin Besudotox 57 NASDAQ SNTA 57 Eprodisate 57 SB# ONX 57 seliciclib 57 hematological malignancies 57 Phase 1b 57 MET VEGFR2 57 alpha folate receptor 57 BEXXAR 57 IMPACT IMmunotherapy 57 CIMZIA TM certolizumab pegol 57 pharmacodynamic profiles 57 Tesmilifene 57 eltrombopag 57 fluticasone furoate 57 INS# [001] 57 Raptiva ® 57 oral proteasome inhibitor 57 FOLFOX6 chemotherapy regimen 57 Panzem 57 IND CTA 57 evaluating Prochymal 57 Acute Decompensated Heart Failure 57 isatoribine 57 rasagiline tablets 57 acetonide FA 57 BioNumerik 57 HSP# inhibitor 57 COMFORT II 57 Urocortin 2 57 TAXUS Element Stent System 57 torezolid 57 OTCBB NRGX 57 MEK Inhibitor 57 radiolabeled 57 OTCBB PYTO 57 Rebif ® 57 methylnaltrexone bromide 57 TEMODAL 57 TELCYTA 57 Oracea TM 57 candidate AQ4N 57 lupus nephritis 57 Tyrima 56 LT NS# 56 Dasatinib 56 investigational hepatitis C 56 XP# XP# 56 lintuzumab SGN 56 active moiety 56 Ophena TM 56 belinostat 56 evaluating Vectibix 56 HGS ETR1 56 oral picoplatin 56 Onalta ™ 56 investigational antiplatelet agent 56 E1 INT TM 56 Romidepsin 56 NASDAQ SLXP today 56 budesonide foam 56 IND submission 56 Pharmion Corporation 56 omiganan 56 EP #R 56 placebo controlled Phase III 56 oral salmon calcitonin 56 intranasal delivery 56 registrational studies 56 pitavastatin 56 motesanib diphosphate 56 pegylated liposomal doxorubicin 56 Temsirolimus 56 Pre RELAX AHF 56 Nexavar ® 56 PS# [001] 56 OTCBB AOLS 56 Shigamabs R 56 autologous cellular immunotherapy 56 Solid Tumors 56 systemic RNAi therapeutic 56 Nasdaq SNSS 56 Phase 2a Clinical Trial